Now showing items 1-3 of 3

    • CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. 

      Lim, JSJ; Turner, NC; Yap, TA (2016-07)
      Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast ...
    • Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers. 

      Yap, TA; Kristeleit, R; Michalarea, V; Pettitt, SJ; Lim, JSJ; Carreira, S; Roda, D; Miller, R; Riisnaes, R; Miranda, S; Figueiredo, I; Rodrigues, DN; Ward, S; Matthews, R; Parmar, M; Turner, A; Tunariu, N; Chopra, N; Gevensleben, H; Turner, NC; Ruddle, R; Raynaud, FI; Decordova, S; Swales, KE; Finneran, L; Hall, E; Rugman, P; Lindemann, JPO; Foxley, A; Lord, CJ; Banerji, U; Plummer, R; Basu, B; Lopez, JS; Drew, Y; de Bono, JS (2020-10)
      Preclinical studies have demonstrated synergy between PARP and PI3K/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing ...
    • Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. 

      Litchfield, K; Summersgill, B; Yost, S; Sultana, R; Labreche, K; Dudakia, D; Renwick, A; Seal, S; Al-Saadi, R; Broderick, P; Turner, NC; Houlston, RS; Huddart, R; Shipley, J; Turnbull, C (2015-01-22)
      Testicular germ cell tumours (TGCTs) are the most common cancer in young men. Here we perform whole-exome sequencing (WES) of 42 TGCTs to comprehensively study the cancer's mutational profile. The mutation rate is uniformly ...